19 June 2013 - 19 June 2013 - US data analytics company CollabRx Inc (NASDAQ:CLRX) said Tuesday it had partnered with the thoracic oncology programme at the University of Chicago Medical Center on clinical cancer sequencing and interpretation.

Under the deal, the parties will combine CollabRx's content and technology resources with the results of genetic sequencing-based tests carried out at the University of Chicago. The tests allow doctors to take into account a tumour's unique genetic profile in cancer treatment planning.

The partnership will be led at the University of Chicago Medical Center by Dr. Ravi Salgia, a professor of medicine and vice chairman of translational research at the university.